Relapse · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with relapse Risk ratio (M‐H, random, 95% CI) compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants who dropped out for AEs Risk ratio (M‐H,… compared with glatiramer acetate (low certainty).
1 finding from 1 review
Mean number of active T2 lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean number of new enhancing lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T2‐hyperintense lesion load Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T1‐hypointense lesion load · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Remission · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review